Ludger is a bioscience company specialising in analytical technology for medical applications of glycobiology. The technology originated at the University of Oxford, UK. It is used in the quality control of FDA- and EMEA-approved biopharmaceuticals worldwide, and can be used to support IND submissions. We have been operating since 1999 and have built up a client base including leading pharmaceutical and biotechnology companies throughout the world.
Ludger is an ISO9001 Registered Company. Ludger operates a Quality Management System (QMS) which covers all aspects of the company's operations, including glycoprofiling contract analysis, and is based on the ISO 9001:2008 registration framework.
Ludger's Head Office, R&D, analytical services and production laboratories are located within the U.K Bioscience 'golden triangle' (Oxford-Cambridge-London) at the Culham Science Centre, Oxfordshire, UK.
Ludger also has a subsidiary office in Shanghai, China:
Ludger Shanghai Biological Technology Co. Ltd
Address: Plaza 66, 15/F, Tower 2, 1266 West Nanjing Road, Jing'An District, Shanghai 200040, China
Technology for Analysis of Glycoprotein Therapeutics
Ludger manufactures a comprehensive range of kits and reagents for ICH-compliant glycoprofiling of biopharmaceuticals throughout the drug development cycle. Our catalogue includes kits for glycan release, labelling and purification. We also sell labelled glycans, glycan HPLC columns, enzymes and glycoprotein standards. Ludger is committed to ongoing new product development to ensure that there are high quality products available to you.
Glycoprofiling Services for Biopharmaceutical Realisation
We can design and execute appropriate glycoprofiling programmes for your therapeutic and transfer optimised glycoprofiling methods to your laboratories. Our analytical services for glycan characterization include: sialic acid profiling (to compare levels of NeuAc vs NeuGc), quantitative monosaccharide analysis, profiling of N- and O-glycans by a range of orthogonal HPLC and MS methods and detailed exoglycosidase sequencing. We also offer high throughput analysis.
R&D for Biopharmaceuticals and Medical Glycomics
Ludger has an ongoing Research and Development programme dedicated to improving glycan analysis for biopharmaceuticals and medical glycomics. Around half of our R&D is funded by EU grants as part of collaborative research programmes. Our research partners in these programmes include other bioscience companies and academic groups across the EU and include other SMEs, large pharmaceutical companies, clinical laboratories and Universities.
Ludger is a member of the BBSRC - IBCarb network and the Oxfordshire Biotech Network